ESP-01: Phase Ib/IIa started
Esperas began an open-label, Canadian Phase Ib/IIa trial to evaluate 10-200 mg oral
Gathering data...
Products & Solutions
About Biocentury
Contact
Privacy & Legal
- Follow Us
Gathering data...
Esperas began an open-label, Canadian Phase Ib/IIa trial to evaluate 10-200 mg oral